Literature DB >> 17537632

Characterization of dystrophic muscle in golden retriever muscular dystrophy dogs by nuclear magnetic resonance imaging.

J-L Thibaud1, A Monnet, D Bertoldi, I Barthélémy, S Blot, P G Carlier.   

Abstract

The Golden Retriever Muscular Dystrophy dog lacks dystrophin. Disease progression in this model shares many similarities with the Duchenne muscular dystrophy, both from anatomico pathological and clinical standpoints. The model is increasingly used in pre-clinical trials but needs to be further investigated, particularly with reference to the evaluation of therapies. The aim of this study was to identify quantitative indices that would help characterize the dystrophic dog non-invasively using NMR imaging. Two-month-old dystrophic dogs and healthy control animals were scanned at 4T. Standard T2- and T1-weighted images, fat-saturated T1-weighted images pre- and post-gadolinium chelate injection were acquired and kinetics of muscle enhancement were studied over a 2-h period. Several indices were found to be abnormally high in dystrophic dogs: the T2-weighted/T1-weighted signal ratio, T2-weighted image heterogeneity and maximal signal enhancement post-gadolinium. These may be proposed to evaluate muscle structural alterations non-invasively in this disease.

Entities:  

Mesh:

Year:  2007        PMID: 17537632     DOI: 10.1016/j.nmd.2007.03.013

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  22 in total

1.  A computerized MRI biomarker quantification scheme for a canine model of Duchenne muscular dystrophy.

Authors:  Jiahui Wang; Zheng Fan; Krista Vandenborne; Glenn Walter; Yael Shiloh-Malawsky; Hongyu An; Joe N Kornegay; Martin A Styner
Journal:  Int J Comput Assist Radiol Surg       Date:  2013-01-09       Impact factor: 2.924

Review 2.  Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Authors:  Joe N Kornegay; Janet R Bogan; Daniel J Bogan; Martin K Childers; Juan Li; Peter Nghiem; David A Detwiler; C Aaron Larsen; Robert W Grange; Ratna K Bhavaraju-Sanka; Sandra Tou; Bruce P Keene; James F Howard; Jiahui Wang; Zheng Fan; Scott J Schatzberg; Martin A Styner; Kevin M Flanigan; Xiao Xiao; Eric P Hoffman
Journal:  Mamm Genome       Date:  2012-01-05       Impact factor: 2.957

Review 3.  Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials.

Authors:  Pierre G Carlier; Benjamin Marty; Olivier Scheidegger; Paulo Loureiro de Sousa; Pierre-Yves Baudin; Eduard Snezhko; Dmitry Vlodavets
Journal:  J Neuromuscul Dis       Date:  2016-03-03

4.  Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in duchenne muscular dystrophy dogs.

Authors:  Karl Rouger; Thibaut Larcher; Laurence Dubreil; Jack-Yves Deschamps; Caroline Le Guiner; Gregory Jouvion; Bruno Delorme; Blandine Lieubeau; Marine Carlus; Benoît Fornasari; Marine Theret; Priscilla Orlando; Mireille Ledevin; Céline Zuber; Isabelle Leroux; Stéphane Deleau; Lydie Guigand; Isabelle Testault; Elisabeth Le Rumeur; Marc Fiszman; Yan Chérel
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

Review 5.  Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy.

Authors:  Erika L Finanger; Barry Russman; Sean C Forbes; William D Rooney; Glenn A Walter; Krista Vandenborne
Journal:  Phys Med Rehabil Clin N Am       Date:  2011-12-14       Impact factor: 1.784

6.  Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.

Authors:  Adeline Vulin; Inès Barthélémy; Aurélie Goyenvalle; Jean-Laurent Thibaud; Cyriaque Beley; Graziella Griffith; Rachid Benchaouir; Maëva le Hir; Yves Unterfinger; Stéphanie Lorain; Patrick Dreyfus; Thomas Voit; Pierre Carlier; Stéphane Blot; Luis Garcia
Journal:  Mol Ther       Date:  2012-09-11       Impact factor: 11.454

7.  RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice.

Authors:  Xiaodong Mu; Arvydas Usas; Ying Tang; Aiping Lu; Bing Wang; Kurt Weiss; Johnny Huard
Journal:  FASEB J       Date:  2013-05-23       Impact factor: 5.191

Review 8.  Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Miranda D Grounds; Hannah G Radley; Gordon S Lynch; Kanneboyina Nagaraju; Annamaria De Luca
Journal:  Neurobiol Dis       Date:  2008-04-09       Impact factor: 5.996

9.  Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.

Authors:  Caroline Le Guiner; Marie Montus; Laurent Servais; Yan Cherel; Virginie Francois; Jean-Laurent Thibaud; Claire Wary; Béatrice Matot; Thibaut Larcher; Lydie Guigand; Maeva Dutilleul; Claire Domenger; Marine Allais; Maud Beuvin; Amélie Moraux; Johanne Le Duff; Marie Devaux; Nicolas Jaulin; Mickaël Guilbaud; Virginie Latournerie; Philippe Veron; Sylvie Boutin; Christian Leborgne; Diana Desgue; Jack-Yves Deschamps; Sophie Moullec; Yves Fromes; Adeline Vulin; Richard H Smith; Nicolas Laroudie; Frédéric Barnay-Toutain; Christel Rivière; Stéphanie Bucher; Thanh-Hoa Le; Nicolas Delaunay; Mehdi Gasmi; Robert M Kotin; Gisèle Bonne; Oumeya Adjali; Carole Masurier; Jean-Yves Hogrel; Pierre Carlier; Philippe Moullier; Thomas Voit
Journal:  Mol Ther       Date:  2014-08-04       Impact factor: 11.454

10.  Effects of an immunosuppressive treatment in the GRMD dog model of Duchenne muscular dystrophy.

Authors:  Inès Barthélémy; Ane Uriarte; Carole Drougard; Yves Unterfinger; Jean-Laurent Thibaud; Stéphane Blot
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.